BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company, will announce its interim results for the six months ended 30 June 2022 on 27 September 2022.
On the same day, the Company will be holding an analyst and investor event, including an overview of its interim results, in London from 14:00 BST (09:00 ET). The event will also be accessible via webcast and a recording of the presentation will be made available on the Company’s website afterwards.
To register your interest in attending either in person or virtually, please contact FTI Consulting at BenevolentAI@fticonsulting.com or +44 (0) 20 3727 1000.
